These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 17895486)

  • 1. Simplified pharmacoeconomics of critical care and severe sepsis.
    Ernst FR; Levy H; Qualy RL
    J Intensive Care Med; 2007; 22(5):283-93. PubMed ID: 17895486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis.
    Frampton JE; Foster RH
    Pharmacoeconomics; 2004; 22(7):445-76. PubMed ID: 15137883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany.
    Neilson AR; Burchardi H; Chinn C; Clouth J; Schneider H; Angus D
    J Crit Care; 2003 Dec; 18(4):217-27. PubMed ID: 14691895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of drotrecogin alfa (activated) on resource use and implications for reimbursement.
    Dasta JF; Cooper LM
    Pharmacotherapy; 2002 Dec; 22(12 Pt 2):216S-222S. PubMed ID: 12492228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should health care money in South Africa be spent on drotrecogin alfa?
    Taylor B; Burns D; van de Wal BW; MBewu T; Keeton GR
    S Afr Med J; 2003 Jul; 93(7):500-1. PubMed ID: 12939917
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of drotrecogin alfa (activated).
    Tsitanidis J
    Crit Care Med; 2003 Sep; 31(9):2414-5; author reply 2415. PubMed ID: 14501983
    [No Abstract]   [Full Text] [Related]  

  • 7. Appraisal of treatment for severe sepsis in intensive care units.
    Burchell M; Ruiz F; Barnett D
    Ann R Coll Surg Engl; 2005 Jul; 87(4):283-4. PubMed ID: 16888847
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.
    Davies A; Ridley S; Hutton J; Chinn C; Barber B; Angus DC
    Anaesthesia; 2005 Feb; 60(2):155-62. PubMed ID: 15644013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of drotrecogin alfa (activated) in older patients with severe sepsis.
    Alexander SL; Ernst FR
    Pharmacotherapy; 2006 Apr; 26(4):533-8. PubMed ID: 16553513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The economics of sepsis.
    Chalupka AN; Talmor D
    Crit Care Clin; 2012 Jan; 28(1):57-76, vi. PubMed ID: 22123099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An economic evaluation of activated protein C treatment for severe sepsis.
    Manns BJ; Lee H; Doig CJ; Johnson D; Donaldson C
    N Engl J Med; 2002 Sep; 347(13):993-1000. PubMed ID: 12324556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drotrecogin alfa (activated) in South African private hospital ICUs.
    Hodgson RE; Williams PG; Foden AP; Grolman D
    S Afr Med J; 2003 Jul; 93(7):474-5. PubMed ID: 12939910
    [No Abstract]   [Full Text] [Related]  

  • 13. [A word of warning about economic evaluations].
    de Solà-Morales O; Pons JM
    Gac Sanit; 2004; 18(6):486; author reply 487-8. PubMed ID: 15625049
    [No Abstract]   [Full Text] [Related]  

  • 14. When is critical care medicine cost-effective? A systematic review of the cost-effectiveness literature.
    Talmor D; Shapiro N; Greenberg D; Stone PW; Neumann PJ
    Crit Care Med; 2006 Nov; 34(11):2738-47. PubMed ID: 16957636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drotrecogin alfa (recombinant human activated protein C) in severe sepsis--a New Zealand viewpoint.
    Liang J; Streat S; Torrance J; Sleigh J; Freebairn R; Ramsay M
    N Z Med J; 2003 Sep; 116(1181):U586. PubMed ID: 14581969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A price for cost-effectiveness: implications for recombinant human activated protein C (rhAPC).
    Chalfin DB; Teres D; Rapoport J
    Crit Care Med; 2003 Jan; 31(1):306-8. PubMed ID: 12545034
    [No Abstract]   [Full Text] [Related]  

  • 17. Meeting unmet needs in patients with sepsis: the role of drotrecogin alfa (activated).
    Morris PE
    Am J Crit Care; 2003 Mar; 12(2):94-7. PubMed ID: 12625165
    [No Abstract]   [Full Text] [Related]  

  • 18. [Medical-economic evaluation of severe sepsis].
    Guidet B
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():28-30. PubMed ID: 15359937
    [No Abstract]   [Full Text] [Related]  

  • 19. Meeting unmet needs in patients with sepsis: the role of drotrecogin alfa (activated).
    McEvoy M
    Am J Crit Care; 2003 Sep; 12(5):398; author reply 398. PubMed ID: 14503421
    [No Abstract]   [Full Text] [Related]  

  • 20. Drotrecogin alfa: a role in emergency department treatment of severe sepsis?
    McLeay AM
    Emerg Med Australas; 2004 Aug; 16(4):324-35. PubMed ID: 15283720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.